LakeShore Biopharma Co., Ltd Price & Performance (LSB)

YS Biopharma has received a further 180-day extension from Nasdaq to meet the minimum $1.00 bid price requirement. The company now has until October 21, 2024, to regain compliance or risk delisting. This extension follows ongoing efforts to stabilize its share price and strengthen investor confidence.12

YS Biopharma is rebranding to LakeShore Biopharma, with the name change effective May 24, 2024, and a new Nasdaq ticker 'LSB' debuting May 28. This strategic move aims to reinforce the company’s global identity, while shareholder rights and financial standing remain unchanged.23

YS Biopharma continues to advance its innovative vaccine pipeline, including pivotal Phase 3 trials for its proprietary PIKA rabies vaccine and early-stage development for hepatitis B and cancer therapies. These R&D efforts highlight the company’s commitment to addressing unmet needs in infectious disease and oncology.42